2014
DOI: 10.1186/1471-2466-14-174
|View full text |Cite
|
Sign up to set email alerts
|

Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2

Abstract: BackgroundEpithelial-mesenchymal transition (EMT) has been believed to be related with chemotherapy resistance in non-small cell lung cancer (NSCLC). Recent studies have suggested eIF5A-2 may function as a proliferation-related oncogene in tumorigenic processes.MethodsWe used cell viability assays, western blotting, immunofluorescence, transwell-matrigel invasion assay, wound-healing assay combined with GC7 (a novel eIF5A-2 inhibitor) treatment or siRNA interference to investigate the role of eIF5A-2 playing i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
39
0
2

Year Published

2015
2015
2023
2023

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 47 publications
(44 citation statements)
references
References 38 publications
3
39
0
2
Order By: Relevance
“…Data from the present study demonstrated that EIF5A2 was overexpressed in NSCLC cells compared with cells from adjacent non-cancerous lung tissues, which is in agreement with the results of previous studies (11,13). NSCLC cells treated with EIF5A2 siRNA exhibited significantly reduced proliferation, significantly increased rates of apoptosis, and significantly reduced abilities to migrate and invade.…”
Section: Discussionsupporting
confidence: 81%
See 1 more Smart Citation
“…Data from the present study demonstrated that EIF5A2 was overexpressed in NSCLC cells compared with cells from adjacent non-cancerous lung tissues, which is in agreement with the results of previous studies (11,13). NSCLC cells treated with EIF5A2 siRNA exhibited significantly reduced proliferation, significantly increased rates of apoptosis, and significantly reduced abilities to migrate and invade.…”
Section: Discussionsupporting
confidence: 81%
“…Downregulation of EIF5A2 prevents EMT in NSCLC (11), while overexpression of EIF5A2 is an adverse prognostic marker of survival for patients with stage I NSCLC (12). In addition, it has been demonstrated that inhibition of EIF5A2 enhances NSCLC sensitivity to chemotherapeutics, prevents or reverses EMT, and reduces the migration and invasion capabilities of NSCLC cells (13).…”
Section: Introductionmentioning
confidence: 99%
“…Its over-expression, usually visualized by IHC, has been observed in cancer of the ovary [55, 74], colorectal carcinoma [75], bladder cancer [59, 76, 77], hepatocellular carcinoma [78, 79], non-small cell lung cancer [80, 81], pancreatic cancer [66], esophageal squamous cell carcinoma [35], and gastric cancer [82]. Both eIF5A1 and eIF5A2 isoforms are present in hepatocellular [57] and pancreatic [66] cancer.…”
Section: Eif5a2 Association With Cancermentioning
confidence: 99%
“…Small molecule inhibitors of DHS and DOHH, such as the spermidine analog GC7 and the drug ciclopirox (Figure 1), mimic many of these effects; conversely, eIF5A2 overexpression increases these mobility and metastatic properties in many of the same cell types. Correspondingly, eIF5A2 silencing and overexpression experiments demonstrated that the protein favors the metastasis-related epithelial-mesenchymal transition (EMT), as reflected in changes in the levels of epithelial cell markers such as E-cadherin and β-catenin and mesenchymal markers such as fibronectin and vimentin [35, 78, 81-83]. …”
Section: Molecular and Cell Biological Basis Of Eif5a2 Action In Cancermentioning
confidence: 99%
See 1 more Smart Citation